Loading...

ContraFect

Nasdaq:CFRX
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CFRX
Nasdaq
$39M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • ContraFect has significant price volatility in the past 3 months.
CFRX Share Price and Events
7 Day Returns
-1.1%
NasdaqCM:CFRX
2.8%
US Biotechs
0.1%
US Market
1 Year Returns
-81.6%
NasdaqCM:CFRX
-5.6%
US Biotechs
1.2%
US Market
CFRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ContraFect (CFRX) -1.1% 7.1% 5.4% -81.6% -83.7% -
US Biotechs 2.8% 1.7% -6% -5.6% 14.4% 9.6%
US Market 0.1% 0.6% 0.9% 1.2% 36.7% 37.9%
1 Year Return vs Industry and Market
  • CFRX underperformed the Biotechs industry which returned -5.6% over the past year.
  • CFRX underperformed the Market in United States of America which returned 1.2% over the past year.
Price Volatility
CFRX
Industry
5yr Volatility vs Market
Related Companies

CFRX Value

 Is ContraFect undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ContraFect to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ContraFect.

NasdaqCM:CFRX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:CFRX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.323 (1 + (1- 21%) (10.61%))
1.291
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.29
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.291 * 5.96%)
10.42%

Discounted Cash Flow Calculation for NasdaqCM:CFRX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ContraFect is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqCM:CFRX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.42%)
2019 -10.90 Analyst x1 -9.87
2020 -30.80 Analyst x1 -25.26
2021 -32.94 Analyst x1 -24.47
2022 -39.60 Analyst x1 -26.64
2023 39.82 Analyst x1 24.25
2024 45.25 Est @ 13.65% 24.96
2025 49.94 Est @ 10.37% 24.95
2026 53.98 Est @ 8.08% 24.42
2027 57.47 Est @ 6.47% 23.55
2028 60.55 Est @ 5.35% 22.47
Present value of next 10 years cash flows $58.38
NasdaqCM:CFRX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $60.55 × (1 + 2.73%) ÷ (10.42% – 2.73%)
$808.71
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $808.71 ÷ (1 + 10.42%)10
$300.09
NasdaqCM:CFRX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $58.38 + $300.09
$358.47
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $358.47 / 79.41
$4.51
NasdaqCM:CFRX Discount to Share Price
Calculation Result
Value per share (USD) From above. $4.51
Current discount Discount to share price of $0.49
= -1 x ($0.49 - $4.51) / $4.51
89.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ContraFect is available for.
Intrinsic value
>50%
Share price is $0.49 vs Future cash flow value of $4.51
Current Discount Checks
For ContraFect to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ContraFect's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ContraFect's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ContraFect's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ContraFect's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:CFRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.09
NasdaqCM:CFRX Share Price ** NasdaqCM (2019-06-18) in USD $0.49
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.39x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ContraFect.

NasdaqCM:CFRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CFRX Share Price ÷ EPS (both in USD)

= 0.49 ÷ -0.09

-5.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ContraFect is loss making, we can't compare its value to the US Biotechs industry average.
  • ContraFect is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does ContraFect's expected growth come at a high price?
Raw Data
NasdaqCM:CFRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
6.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.11x
United States of America Market PEG Ratio Median Figure of 2,126 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ContraFect, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ContraFect's assets?
Raw Data
NasdaqCM:CFRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.22
NasdaqCM:CFRX Share Price * NasdaqCM (2019-06-18) in USD $0.49
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqCM:CFRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CFRX Share Price ÷ Book Value per Share (both in USD)

= 0.49 ÷ 0.22

2.2x

* Primary Listing of ContraFect.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ContraFect is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess ContraFect's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ContraFect has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CFRX Future Performance

 How is ContraFect expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ContraFect expected to grow at an attractive rate?
  • ContraFect's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • ContraFect's earnings growth is positive but not above the United States of America market average.
  • Unable to compare ContraFect's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:CFRX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:CFRX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 6.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:CFRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:CFRX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 73 39 2
2022-12-31 5 -40 2
2021-12-31 0 -36 3
2020-12-31 0 -34 5
2019-12-31 0 -28 -9 5
NasdaqCM:CFRX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -27 -7
2018-12-31 -26 -38
2018-09-30 -25 -48
2018-06-30 -25 -46
2018-03-31 -25 -28
2017-12-31 -25 -16
2017-09-30 -27 -10
2017-06-30 -29 -19
2017-03-31 -29 -26
2016-12-31 -29 -29
2016-09-30 -27 -37
2016-06-30 -25 -32

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ContraFect's earnings are expected to grow by 6.6% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if ContraFect is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:CFRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from ContraFect Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CFRX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.29 0.29 0.29 1.00
2022-12-31 -0.30 -0.30 -0.30 1.00
2021-12-31 -0.33 -0.26 -0.39 2.00
2020-12-31 -0.35 -0.25 -0.53 5.00
2019-12-31 -0.09 -0.03 -0.13 5.00
NasdaqCM:CFRX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.09
2018-12-31 -0.50
2018-09-30 -0.65
2018-06-30 -0.64
2018-03-31 -0.44
2017-12-31 -0.28
2017-09-30 -0.21
2017-06-30 -0.47
2017-03-31 -0.70
2016-12-31 -0.85
2016-09-30 -1.23
2016-06-30 -1.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ContraFect will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ContraFect's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ContraFect has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CFRX Past Performance

  How has ContraFect performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ContraFect's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ContraFect does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare ContraFect's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ContraFect's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ContraFect's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ContraFect Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CFRX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -6.99 8.71 21.00
2018-12-31 -37.68 8.71 21.73
2018-09-30 -48.38 9.37 19.75
2018-06-30 -45.57 9.08 19.43
2018-03-31 -28.28 9.16 17.89
2017-12-31 -15.52 9.05 16.83
2017-09-30 -10.17 10.42 16.61
2017-06-30 -19.12 10.57 17.27
2017-03-31 -25.96 10.85 20.33
2016-12-31 -28.54 11.43 20.51
2016-09-30 -36.72 9.24 20.67
2016-06-30 -31.76 9.66 17.92
2016-03-31 -29.19 9.91 15.19
2015-12-31 -25.12 10.06 13.68
2015-09-30 -22.27 10.00 11.17
2015-06-30 -33.10 9.91 10.45
2015-03-31 -34.26 8.22 7.86
2014-12-31 -34.62 8.07 6.91
2014-09-30 -40.81 6.88 6.33
2014-06-30 -28.77 6.07 6.27
2014-03-31 -24.43 6.66 6.98
2013-12-31 -23.62 6.56 7.96
2013-09-30 -18.56 6.79 9.29
2013-06-30 -20.06 6.87 9.88
2013-03-31 -19.91 6.54 10.04
2012-12-31 -19.28 5.94 10.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ContraFect has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ContraFect has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ContraFect improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ContraFect's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ContraFect has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CFRX Health

 How is ContraFect's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ContraFect's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ContraFect is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ContraFect's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ContraFect's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ContraFect has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ContraFect Company Filings, last reported 2 months ago.

NasdaqCM:CFRX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 17.48 4.09 23.09
2018-12-31 5.54 0.00 30.45
2018-09-30 -0.70 0.00 37.60
2018-06-30 -7.16 0.00 33.29
2018-03-31 12.51 0.00 39.85
2017-12-31 31.19 0.00 46.85
2017-09-30 35.47 0.00 52.55
2017-06-30 11.09 0.00 21.71
2017-03-31 13.55 0.00 28.89
2016-12-31 19.51 0.00 35.16
2016-09-30 18.55 0.00 43.21
2016-06-30 13.77 0.00 19.09
2016-03-31 22.86 0.00 26.27
2015-12-31 30.68 0.00 32.92
2015-09-30 28.17 0.00 29.46
2015-06-30 33.13 0.00 35.26
2015-03-31 21.10 0.00 22.88
2014-12-31 25.58 0.00 27.39
2014-09-30 29.51 0.00 31.32
2014-06-30 -25.62 12.36 2.19
2014-03-31 -17.58 10.83 2.54
2013-12-31 -13.02 9.82 4.15
2013-09-30
2013-06-30 0.18 8.96 9.59
2013-03-31 7.66 1.90 7.89
2012-12-31 7.66 1.90 7.89
  • ContraFect has no debt.
  • ContraFect currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ContraFect has less than a year of cash runway based on current free cash flow.
  • ContraFect has less than a year of cash runway if free cash flow continues to reduce at historical rates of -1.3% each year.
X
Financial health checks
We assess ContraFect's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ContraFect has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CFRX Dividends

 What is ContraFect's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ContraFect dividends.
If you bought $2,000 of ContraFect shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ContraFect's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ContraFect's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:CFRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:CFRX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ContraFect has not reported any payouts.
  • Unable to verify if ContraFect's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ContraFect's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ContraFect has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ContraFect's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ContraFect afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ContraFect has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CFRX Management

 What is the CEO of ContraFect's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Roger Pomerantz
COMPENSATION $90,214
AGE 61
TENURE AS CEO 0.2 years
CEO Bio

Dr. Roger James Pomerantz, M.D., F.A.C.P. has been Chairman and Chief Executive Officer of ContraFect Corporation since April 2, 2019 and serves as its President. He served as Venture Partner of Flagship Pioneering (formerly known as Flagship Ventures). He joined the firm in 14th July 2014. He served as a senior partner at the firm. Dr. Pomerantz focused on providing strategic counsel and support to the Flagship team as well as to portfolio companies through board and advisory roles. Dr. Pomerantz had been the Chief Executive Officer and President of Seres Therapeutics, Inc. (formerly, Seres Health, Inc.) since June 2014 until January 15, 2018. He is the Chairman of Scientific Advisory Board at Aridis Pharmaceuticals, Inc. He has been the President of Tibotec-Virco NV since September 2005. Dr. Pomerantz serves as the President of Janssen R&D Ireland. Dr. Pomerantz served as Senior Vice President of Johnson and Johnson, Inc. From January 2011 to September 2013, he served as Senior Vice President and Worldwide Head of Licensing & Acquisitions at Merck & Co., Inc., where he oversaw licensing and acquisitions for Merck Research Laboratories, the research and development division of Merck. He was Global Franchise Head of Infectious Diseases and Senior Vice President at Merck Research Laboratories, where he oversaw pharmaceutical development and discovery of antibiotics, antivirals, antifungals and antiparasitic agents. Dr. Pomerantz has extensive academic and clinical experience, as well as knowledge in the pharmaceutical industry. Prior to joining Merck, he served as the Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He was responsible for anti-infective agents worldwide. He joined Johnson & Johnson in August 2005 as the President of Tibotec Pharmaceuticals, Inc. (now Janssen Therapeutics). He served as the President of Janssen Infectious Diseases-Diagnostics BVBA since September 1, 2005. He served as Chief of Infectious Diseases and the Founding Director and Chairman of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He was a Professor of Medicine, Biochemistry and Molecular Pharmacology at Thomas Jefferson University and Medical School. He has been Director of Intec Pharma Ltd. since March 22, 2018. He has been the Chairman of the Board of Seres Therapeutics, Inc. since November 21, 2013. He was Vice Chairman of ContraFect Corporation from May 2014 to April 2, 2019 and has been its Director since April 2014. He has been the Chair of Scientific Advisory Board at Novira Therapeutics, Inc. since August 26, 2014. He serves as a Director of Rubius Therapeutics, Inc. since December 2014. He serves as a Member of Scientific Advisory Board at BSI Healthcapital SA. He served as a Director of Evelo Therapeutics, Inc. until May 31, 2016. He has so far developed twelve small and large molecule drugs approved world-wide in critical human diseases, including HIV, HCV, CMV, C. difficile and multi-drug resistant tuberculosis. He is Board Certified in both Internal Medicine and Infectious Diseases. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute at M.I.T., in the laboratory of Nobel Laureate, Dr. David Baltimore. He completed his Internal Medicine internship and residency training and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (MGH) and served as the Chief Medical Resident at MGH. He received his B.A. in Biochemistry from the Johns Hopkins University and his M.D. from the Johns Hopkins School of Medicine. He received Post-Graduate Training from the Massachusetts General Hospital, where he was also Chief Resident, Harvard Medical School and M.I.T.

CEO Compensation
  • Roger's compensation has increased whilst company is loss making.
  • Roger's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ContraFect management team in years:

2.5
Average Tenure
54.5
Average Age
  • The tenure for the ContraFect management team is about average.
Management Team

Roger Pomerantz

TITLE
Chairman
COMPENSATION
$90K
AGE
61
TENURE
0.2 yrs

Natalie Bogdanos

TITLE
General Counsel
COMPENSATION
$746K
AGE
49
TENURE
4.8 yrs

Cara Cassino

TITLE
Chief Medical Officer and Executive VP of Research & Development
COMPENSATION
$1M
AGE
56
TENURE
3.7 yrs

Mike Messinger

TITLE
CFO & Chief Accounting Officer
COMPENSATION
$616K
AGE
43
TENURE
0.6 yrs

Nancy Dong

TITLE
Vice President of Finance & Administration
COMPENSATION
$482K
AGE
53
TENURE
2.3 yrs

Mike Wittekind

TITLE
Consultant
COMPENSATION
$794K
AGE
63
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the ContraFect board of directors in years:

4.6
Average Tenure
65.5
Average Age
  • The tenure for the ContraFect board of directors is about average.
Board of Directors

Roger Pomerantz

TITLE
Chairman
COMPENSATION
$90K
AGE
61
TENURE
0.2 yrs

Steve Gilman

TITLE
Vice Chairman
COMPENSATION
$1M
AGE
65
TENURE
0.2 yrs

Vince Fischetti

TITLE
Chairman of Scientific Advisory Board

Sol Barer

TITLE
Lead Independent Director
COMPENSATION
$95K
AGE
71
TENURE
4.1 yrs

David Low

TITLE
Independent Director
COMPENSATION
$85K
AGE
59
TENURE
5.2 yrs

Michael Otto

TITLE
Independent Director
COMPENSATION
$78K
AGE
69
TENURE
5.2 yrs

Peter Palese

TITLE
Member of Scientific Advisory Board

Adolfo Garcia-Sastre

TITLE
Member of Scientific Advisory Board

Cary Sucoff

TITLE
Independent Director
COMPENSATION
$76K
AGE
66
TENURE
9.1 yrs

Leon Smith

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
06. Dec 18 Sell Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Company 04. Dec 18 04. Dec 18 -600,000 $2.04 $-1,224,000
X
Management checks
We assess ContraFect's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ContraFect has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CFRX News

Simply Wall St News

What Kind Of Shareholder Appears On The ContraFect Corporation's (NASDAQ:CFRX) Shareholder Register?

As Charlie Munger said 'Show me the incentive and I will show you the outcome.' With a market capitalization of US$37m, ContraFect is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for ContraFect NasdaqCM:CFRX Ownership Summary, June 14th 2019 What Does The Institutional Ownership Tell Us About ContraFect? … We can see that ContraFect does have institutional investors; and they hold 26% of the stock.

Simply Wall St -

What Kind Of Shareholders Own ContraFect Corporation (NASDAQ:CFRX)?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … ContraFect is a smaller company with a market capitalization of US$32m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

What Kind Of Investor Owns Most Of ContraFect Corporation (NASDAQ:CFRX)?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … ContraFect is a smaller company with a market capitalization of US$165m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

What Does ContraFect Corporation's (NASDAQ:CFRX) Ownership Structure Look Like?

In this article, I will take a quick look at ContraFect Corporation’s (NASDAQ:CFRX) recent ownership structure – an unconventional investing subject, but an important one. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Are You Backing The Right Horse With ContraFect Corporation (CFRX)?

The demand for new drug development to meet new or persistent chronic illnesses, as well as the ongoing need for biotech drugs as Baby Boomers continue to age, are growth drivers for the optimistic outlook for the biotech industry in the long run. … Over the past year, the industry saw growth of 8.45%, though still underperforming the wider US stock market. … If CFRX has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

CFRX Company Info

Description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Details
Name: ContraFect Corporation
CFRX
Exchange: NasdaqCM
Founded: 2008
$38,513,634
79,409,556
Website: http://www.contrafect.com
Address: ContraFect Corporation
28 Wells Avenue,
3rd Floor,
Yonkers,
New York, 10701,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CFRX Common Stock Nasdaq Capital Market US USD 15. Sep 2014
Number of employees
Current staff
Staff numbers
20
ContraFect employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/19 00:48
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/06/11
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.